Business and Finance

RACollab.org invites trade and channel execs to participate

HHS Azar announces a plan to make a plan, roughly in time to be a talking point in next year’s national election

Increase of 3.8% over 2018; drug costs up 2.1%

2019 survey results characterize the field by job, managment level and location

HDA Research Foundation highlights constraints and additional costs of reimportation

News follows court ruling against advertising retail drug prices

Business Intelligence meets Big Data

A hospital-led supply consortium is only just getting started

Expiration of the blockbuster Humira franchise figures in Abbvie’s planning

Investigative journalist Katherine Eban returns with an indictment of generic drug quality

Kalderos garners $7-million Series A funding from Mercato Partners

New science breakthroughs, and easy access to financing, propel this year’s M&A and licensing market

Will retain position until May 2020

Association will promote its members' value to the public via digital advertising and publishing

Managed Retail Network will offer “light” patient support services through 25,000 pharmacies

The Unstoppable Growth of Prescription Drug Prices

Model N positions itself for coming revisions in pharma trade practices

Acquisition of daVIZta brings more analytics expertise

$21.4-billion acquisition realigns research and manufacturing sourcing

Ex-AmerisourceBergen, -Cardinal and -inVentiv Health execs join team

By working with the sales force, incentive plan design can boost a product launch

Will restricting use of rebates in federal programs carry over to commercial insurance?

Senate and House committees begin the legislative process for addressing drug pricing

Annual analysis predicts 3-6% CAGR through 2023, a lower rate than 2014-2018

Even as the science behind the new therapies is getting established, payers are preparing for their extraordinary cost

Spending on drug promotion rose—but not at the rate of pharma sales growth

A deeper commitment to oncology and immunology

Cellular and genetic therapies (CGTs) developers are struggling to build capacity

Oncology represents half of the dollar volume of HDA-member sales

Pfizer’s Ibrance was the star performer from the class of 2015 FDA approvals